1Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels [ J ]. N Engl J Med,1996,335(14) :1001.
1BOODHWANI M, NAKAI Y, VOISINE P,et al. Atorvastatin alters myocardial expression of VEGF and endostatin in hypercholesterolemic swine: implications for angiogenesis[J]. J Am Coll Surg, 2005, 201( 3 ) : S26 - S27.
2The Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study(4S) [J]. Lancet, 1994, 334(8934) : 1383 - 1389.
3JOHN S, SCHNEIDER MP, DELLES C, et al. Lipid-independent effects of statins on endothelial function and bioavailability of nitric oxide in hypercholesterolemic patients[J]. Am Heart J, 2005, 149 (3) :
4SHEPHERD J, COBBE S M, FORD I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Provention Study Group [J]. N Engl J Med,1995, 333(20) : 1301 - 1307.
5HARRISON D G, OHARA Y. Physiologic consequences of increased vascular oxidant stresses in hypercholesterolemia and atherosclerosis:implications of impaired vasomotion [J]. Am J Cardiol, 1995,75 (6) :75B -81B.
6CELERMAJER D S,SORENSEN K E,BULL C,et al. Endothelium-dependent dilation in the systemic arteries of asymptomatic subjects relates to coronary risk factors and their interaction [J]. J Am Coll Cardiol,1994, 24(6) : 1468 - 1474.
7SAKABE K,FUKUDA N,WAKAYAMA K,et al. Lipid-altering changes and pleiotropic effects of atorvastatin in patients with hypercholesterolemia[J]. Am J Cardiol, 2004, 94(4) : 497 -500.
8MALIK J, MELENOVSKY V, WICHTERLE D, et al. Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidaemia (fenofibrate versus atorvastatin trial-FAT) [J]. Cardiovasc Res,2001, 52(2) : 290 -298.
